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I.INTRODUCTION
Patents are as much a part of business as a handshake or playing
eighteen holes on a warm summer morning. They protect our ideas
and give us protection while we desperately try to cultivate the fruits
of our labor. They give innovators a fighting chance in a land of
capitalistic juggernauts, and provide enough hope to encourage the
little guy to pursue his dreams, to invent something new, or to make
something else better. However, unlimited protection would be
impractical and imprudent. Without a proper catalyst, some
inventions are bound to fall short of their potential. Thus, a delicate
balance must be struck in order to encourage innovators to continue
doing what they do best while allowing, at the proper moment, those
with the resources to take those innovations to the market to share
with the rest of the world. The balance between profit and
innovation must remain intact.
Over the years, the area of what is patentable has broadened
considerably. Patents were originally given exclusively to protect
tangible inventions. A person could not replicate a particular
patented good without the permission of the patent holder. But,
patents have proven to be adaptable and have changed along with the
times. Advances in technology called for protection of intangible
goods – protection of ideas or processes, methods of doing things
better than the old way.1 One thing had always remained the same:
Patents were not to be granted on discoveries.

* J.D. Candidate, Pepperdine University School of Law, 2016; B.S. in
Chemistry, 2011, Ball State University. I would like to thank my family and friends
for their support throughout law school and the members of this journal for their
dedication in publishing this Comment.
1
“As one academic has noted: 'IP is now implicated in routine, creative,
communicative, and just plain consumptive acts that each of us perform everyday.
The reach of the rights has been expanded just at the same moment that their
practical effect has been transformed.” Genomics, and the Patenting of DNA:
Review of potential implications for health in developing countries, WORLD
HEALTH ORG. 11 (2005), http://www.who.int/genomics/FullReport.pdf (citing
JAMES BOYLE, SHAMANS, SOFTWARE & SPLEENS: LAW AND THE CONSTRUCTION
OF THE INFORMATION SOCIETY (1996).
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This rule had always seemed clear enough: inventions, yes,
discoveries, no. But we now enter into a time where the dichotomy
between invention and discovery has become murky. Nature is being
put to use.
The patenting of DNA presents an interesting point for
consideration, because it is a topic about which there is great polarity
in views, not only about its effects on research and access, but also
due to more basic misgivings about whether DNA is the right sort of
thing to patent.2
Natural things are being used in unnatural ways, and we, as a
culture, are trying to handle this mash-up in the most practical of
ways, without compromising the integrity of the patent system.
The patenting of genetic materials has brought forth many
considerations. Not only has this practice caused us to reconsider the
line where discovery ends and creation begins, but also several issues
have arisen regarding the current patent standards used to determine
when inventions can be patented. This note considers the current
state of affairs regarding patentability in the field of biotechnology,
especially that of genes and DNA.3 Part II gives a brief background
of patents in general, including the requirements that must be met for
a patent to be granted, the way in which the patent process works,
and the options available to a patent holder once a patent has been
granted.4 Part III explores the history of biotechnology patents.5 Part
IV takes a look at the relationship between patents and
biotechnology, and sheds light on some of the common arguments
both in favor of and against the patenting of genetic material.6 Part V
investigates solutions proposed to remedy the problems raised in Part
III, and considers a different approach to fixing the patent system as

2

WORLD HEALTH ORG., supra note 1 at 48.
Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107,
2111 (2013). The human genome consists of approximately 22,000 genes packed
into twenty-three pairs of chromosomes. Each gene is encoded as DNA, which
takes the shape of the familiar “double helix” that doctors James Watson and
Francis Crick first described in 1953. Each “cross-bar” in the DNA helix consists
of two chemically joined nucleotides. Id.
4
See infra Part II and accompanying notes 8-76.
5
See infra Part III and accompanying notes 77-150.
6
See infra Part IV and accompanying notes 151-197.
3
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it relates to biotechnology.7 Part VI concludes this note by proposing
a slight adaptation to the existing patent system.8
II.BACKGROUND
A. What is a Patent?
“Patents were created as a way to provide financial incentives for
inventors to undertake research, by allowing them to exclude
competitors from exploiting their invention for a specified period of
time.”9 Inventors are given a fair opportunity to commercialize and
make profits as a result of their efforts.10 Patent holders are given
temporary rights that act as a fence blocking off others who try to
access the subject of the patent without a license.11 The primary
objectives of the patent system are: (1) to encourage the disclosure
of technological advances and findings to the public, and (2) to
incentivize inventors by rewarding their efforts.12 In the United
States, patent protection arises from Congress’s Constitutional
authority “[t]o promote the Progress of … useful Arts, by securing
for limited Times to … Inventors the exclusive Right to their …
Discoveries.”13 Making use of this power, Congress enacted Title 35
of the United States Code, which governs all United States patent
law.14 There are four parts within the title.15 Within those four parts,
thirty-seven chapters with 376 sections can be found.16 Part I
establishes the United States Patent and Trademark Office

7

See infra Part V and accompanying notes 198-249.
See infra Part V.
9
WORLD HEALTH ORG., supra note 1 at 9.
10
See id.
11
See id.
12
Sara Dastgheib-Vinarov, A Higher Nonobviousness Standard for Gene
Patents: Protecting Biomedical Research from the Big Chill, 4 MARQ. INTELL.
PROP. L. REV. 143 (2000).
13
U.S. CONST. art. I, § 8, cl. 8.
14
35 U.S.C §§ 1-376.
15
Id.
16
Id.
8
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(USPTO)17 and gives the USPTO the powers necessary to run the
United States patent system.18 As defined by the USPTO:
A patent is a property right granted by the Government of the
United States of America to an inventor ‘to exclude others from
making, using, offering for sale, or selling the invention throughout
the United States or importing the invention into the United States’
for a limited time in exchange for public disclosure of the invention
when the patent is granted.19
In other words, a patent holder is granted the sole right to exclude
others from making, using, or selling an invention covered by the
patent.20 This right is often for a period of twenty years, assuming a
request for renewal is properly filed and all applicable fees are paid
on time.21
Patent applications are reviewed by the Patent and Trademark
office to ensure that they meet all requirements, including patentable
subject matter,22 utility,23 novelty,24 and nonobviousness.252627
17

Id.
Id.
19
General Information Concerning Patents, UNITED STATES PATENT AND
TRADEMARK OFFICE (Dec. 8, 2014 9:12 AM ET), http://www.uspto.gov/patentsgetting-started/general-information-concerning-patents.
20
PATENT LAW BASICS § 6:1.
21
Id.
22
A patent is granted to “[w]hoever invents or discovers any new and useful
process, machine, manufacture, or composition of matter, or any new and useful
improvement thereof,” subject to the additional requirements of the Patent Act. 35
U.S.C. § 101.
23
“The utility of most mechanical inventions is apparent from an examination
of their structures. Consequently, their utility (or, more precisely, their
operativeness) is presumed.” PATENT LAW BASICS § 8:6 (emphasis added). Some
practical utility for the product of a chemical process must either be apparent to one
skilled in the art or be disclosed in the specification for a patent application with
claims directed to such process to satisfy the utility requirement. PATENT LAW
BASICS § 8:7 (emphasis added).
24
PATENT LAW BASICS § 7:1. “[35 U.S.C.A. § 102] sets forth the novelty
requirement by spelling out just what types of activity negate novelty. It declares:
A person shall be entitled to a patent unless—
(a) the invention was known or used by others in this country . . . or (b) the
invention was patented or described in a printed publication in this or a foreign
country or in public use or on sale in this country, more than one year prior to the
date of the application for patent in the United States, or (c) he has abandoned the
invention, or (d) the invention was first patented or caused to be patented, or was
18
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Section 101 of 35 U.S.C. defines subject matter that is patentable.28
A claim must fit in one and only one of four categories in order to be
proper.29 “These four categories of patentable inventions include
manufacture, machine, composition of matter, and process.”30
Patentable subjects include products,31 processes, products-byprocesses, and living subject matter.32 A product is a “new, useful
and non-obvious machine, manufacture and composition of
matter.”33 Processes are “new, useful and non-obvious way[s] of
the subject of an inventor's certificate, by the applicant or his legal representatives
or assigns in a foreign country prior to the date of the application for patent or
inventor's certificate filed more than twelve months before the filing of the
application in the United States, or (e) the invention was described in . . . (1) an
application for patent . . . (2) a patent granted on an application for patent by
another filed in the United States before the invention by the applicant for patent . .
. .” Id.
25
An invention does not satisfy the nonobvious requirement
if the differences between the subject matter sought to be patented
and the prior art are such that the subject matter as a whole would have
been obvious at the time the invention was made to a person having
ordinary skill in the art to which the said subject matter pertains.
35 U.S.C.A. § 103 (a).
26
Additionally, 35 U.S.C. § 112(a) refers to an enablement requirement. The
Enablement Requirement, U.S. PAT. AND TRADEMARK OFF. (March 27, 2014
10:10:34),http://www.uspto.gov/web/offices/pac/mpep/s2164.html. “The invention
that one skilled in the art must be enabled to make and use is that defined by the
claim(s) of the particular application or patent.” Id. Also, “In addition, the
specification must provide a ‘written description of the invention’ disclosing
sufficient information to enable one of ordinary skill in the art to make and use the
invention, and must present the ‘best mode’ contemplated by the inventor for the
design or operation of that invention.” Dastgheib-Vinarov, supra note 12 at 150
(citing DONALD S. CHISUM ET AL., PRINCIPLES OF PATENT LAW 71 (1998)).
27
Becca Alley, The Biotechnology Process Patent Act of 1995: Providing
Unresolved and Unrecognized Dilemmas in U.S. Patent Law, 12 J. INTELL. PROP.
L. 229 (2004).
28
35 U.S.C. § 101.
29
PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE,
227-229 (2013) (ebook)..
30
Id.
31
Product patents to cover, for example, chemicals, formulations, equipment
and diagnostic kits. An invention covered by a product patent cannot be
reproduced without a license, even if a different method is used to make it. See Id.
32
Id.
33
Id.
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doing, making and using something.”34 A new process for creating a
product may be patented even if the product itself is.35 The opposite
of this concept is found in product-by-process inventions, which
occurs when a product is patentable, but the process is not.36 “Living
subject matter is patentable, but only if human ingenuity is used to
invent the new matter.”37 If the living subject matter is not a result of
human ingenuity, then the naturally occurring living subject matter
may not be patented.38 Today, the constitution of existing “in nature”
is understood to be narrow in patent law in many countries.39 “In
nature” literally means what exists in nature; that is, what exists in its
un-isolated form.40 Methods in which things are accomplished,
designs, and plants (to a certain extent) all fall within the range of
patentability.41
Unpatentable material is classified as a discovery or some subject
matter in which the novel aspects of which require mental activity.42
This may include naturally occurring materials or organisms, or
inventions encompassing a human being at its broadest reasonable
interpretation.43 Laws of mathematics, physics, and processes that
depend on these laws are unpatentable.44 Additionally, printed
matter, methods of doing business, or mental processes are also
unpatentable.45
Section 101 of 35 U.S.C requires a prima facie showing of utility
prior to the granting of a patent.46 “This showing must be
34

Id.
PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE,
227-229 (2013) (ebook).
36
Id.
37
Id.
38
Id.
39
WORLD HEALTH ORG., supra note 1 at 10.
40
Id.
41
PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE,
227-229 (2013) (ebook).
42
PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE,
237 (2013) (ebook).
43
See Id.
44
See Id.
45
See Id.
46
35 U.S.C. § 101.
35
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accompanied by sufficient evidence to support the utility, or
usefulness of the material.”47 Additionally, it is required that the
material be novel, or new.48 “While all . . . requirements are
necessary for patentability, many judges and scholars regard
nonobviousness as the key requirement, in part, because it is
frequently the most challenging to prove.”49 Obviousness has been
determined on a case-by-case basis, and in making this determination
the court must determine the scope and content of previous patents;
differences between those previous patents and the patent at issue;
and the level of skill involved in creating the patentable invention.50
In layman’s terms, the first paragraph of section 103 of 35 U.S.C.
states that a new invention is not patentable if the invention would
have been obvious to a person skilled in the art to which the
invention pertains.51
B. Filing a Patent with the USPTO
The first step in the patent process is to conduct a patent search to
determine whether an invention is likely to be able to be protected.52
Inventions that have not yet been patented may be eligible for
patentability.53 Once it is determined that a particular invention has
not yet been patented, the next step is to determine what type of
application to file.54 Applications may differ depending whether a
design patent,55 a plant patent,56 or, most commonly, a utility patent57
47

PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE,
237 (2013) (ebook).
48
Id.
49
Dastgheib-Vinarov, supra note 12 at 151-52.
50
See infra Part IV for proposed changes in the treatment of the nonobvious
requirement in the field of biotechnology.
51
See Id.
52
Patents, Patent Process Overview, U.S. PAT. AND TRADEMARK OFF. (Nov.
24, 2014 2:40 PM ET), http://www.uspto.gov/patents/process/ppo_textonly.jsp.
53
Id.
54
Id.
55
“[A] ‘design patent’ protects the way an article looks (35 U.S.C. 171).
“Technology Center 2900, Design Patent Application Guide, U.S. PAT.
&TRADEMARK OFF. (Aug. 13, 2012 10:42 AM ET), http://www.uspto.gov/patentsgetting-started/patent-basics/types-patent-applications/design-patent-applicationguide#def.
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is needed.58 The text found in a patent must include “patent claims
that define the subject matter of the invention, as well as all the
elements, features and critical aspects of the invention, so that a
person trained in the relevant scientific discipline should be able to
replicate the invention.”59 The claims in the application define the
patent’s scope, or in other words, how expansive the protection that
is given must be.60 An additional consideration is the type of
coverage that will be needed, for the process may vary depending on
whether international or United States domestic protection is
needed.61 If filing in the United States, an individual seeking a patent
must also decide whether a provisional62 or a nonprovisional63
application is most ideal.64 Applications may then be filed pro se or
through a registered attorney or patent agent.65 After filing, the
56

“A plant patent is granted by the Government to an inventor (or the
inventor's heirs or assigns) who has invented or discovered and asexually
reproduced a distinct and new variety of plant, other than a tuber propagated plant
or a plant found in an uncultivated state.” Technology Center 1600, General
Information About 35 U.S.C. 161 Plant Patents, U.S. PAT. & TRADEMARK OFF.
(Feb. 20, 2015 4:05 PM ET), http://www.uspto.gov/patents-getting-started/patentbasics/types-patent-applications/general-information-about-35-usc-161.
57
“In general terms, a ‘utility patent’ protects the way an article is used and
works (35 U.S.C. 101).” Technology Center 2900, supra note 56.
58
Patents, supra note 52.
59
WORLD HEALTH ORG., supra note 1.
60
Id.
61
Patents, supra note 52.
62
A provisional application for patent has a pendency lasting 12 months from
the date the provisional application is filed. The 12-month pendency period cannot
be extended. Therefore, an applicant who files a provisional application must file a
corresponding nonprovisional application for patent (nonprovisional application)
during the 12-month pendency period of the provisional application in order to
benefit from the earlier filing of the provisional application. Provisional
Application for Patent, U.S. PAT. & TRADEMARK OFF. (Jan. 12, 2015 2:11 PM
ET), http://www.uspto.gov/patents/resources/types/provapp.jsp.
63
A non-provisional patent application, once filed, merely establishes the
filing date of the patent and begins the patent examination process. Id.
64
Patents, supra note 52.
65
Id. One major advantage to filing a pro se application is the avoidance of
costly attorney’s fees. Depending on the amount of technology involved in the
patent, attorney’s may charge anywhere form $5,000.00 to upwards of $15,000.00
to see the application process through. Gene Quinn, The Cost of Obtaining a
Patent in the US, IPWATCHDOG (Apr.4, 2015),
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USPTO examines the application to either grant or reject the
application.66 If rejected, the patent applicant may reply with a
request to reconsider and may appeal as necessary.67 Once granted,
the applicant must pay an issue fee and a publication fee.68 To
preserve a patent for the years-to-come, maintenance fees are due
three-and-a-half, seven-and-a-half, and eleven-and-a-half years after
the original grant.69
C. Licensing patented inventions
Patent holders are given at least two choices as to how to exercise
his or her exclusive rights.70 “First, the patent holder may decide to
be the sole user of the patented invention and exclude all others from
its manufacture, use, or sale.”71 In the alternative, the patent holder
may choose to grant a license to others, giving them “the right to use
the invention under agreed-upon terms.”72 The patent holder may
grant an “exclusive [license] to one licensee, or a non-exclusive
license to several licensees.”73 “Exclusive licenses can include
exemptions, for example for humanitarian or research use.”74
However a patent holder chooses to use the patent, “the patent holder
is able to [create revenue either through the sale of the patented
invention] and services, or through royalties obtained from licensees”

http://www.ipwatchdog.com/2015/04/04/the-cost-of-obtaining-a-patent-in-theus/id=56485/.
66
Patents, supra note 52.
67
Id.
68
Id. Patent application filing fees may range from $140.00 to $780.00. The
major factor in determining the cost of a patent application is the complexity of the
patent. Additional up-front fees and maintenance fees may result in a patent filing
process that costs thousands of dollars. USPTO Fee Schedule, U.S. PAT. &
TRADEMARK OFF. (Feb. 4, 2015 6:14 PM ET),
http://www.uspto.gov/web/offices/ac/qs/ope/fee010114.htm#patapp.
69
Patents, supra note 52.
70
WORLD HEALTH ORG.supra note 1 at 13.
71
Id.
72
Id.
73
Id.
74
Id.
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using the patent.75 This is the financial incentive that makes up the
foundation of patent law.76
III. THE FIELD OF BIOTECHNOLOGY
A. The Patentability of Biotechnology
“At its simplest, biotechnology is technology based on biology biotechnology harnesses cellular and biomolecular processes to
develop technologies and products that help improve our lives and
the health of our planet.”77 In the recent decades, the field of
biotechnology has been stirring up much controversy in the patent
word. “In recent years, this history has been marked by dramatic
changes in the way that lawmakers and courts view and interpret the
system.”78 Biotech generally concerns the application of cellular and
molecular biology to make or modify products and processes for
specific use.79 Biotechnology brings unique challenges to the topic
of patentability, as often biotechnology patents often operate within a
grey area dealing with living organisms.80 Traditionally, living
organisms were truly only products of nature, and therefore remained
unpatentable.81 However, this is no longer the case since advances in
science have resulted in the technology to modify and develop
organisms.82
The manipulation of living or biologically active materially has
contributed greatly to humanity,83 especially with advances made in

75

WORLD HEALTH ORG.supra note 1 at 13.
Id.
77
What is Biotechnology?, BIOTECHNOLOGY INDUS. ORG.,
https://www.bio.org/articles/what-biotechnology (last visited Oct. 22, 2015).
78
Id. at 11.
79
Cf. 1 BIOTECHNOLOGY AND THE LAW § 1:1, Westlaw (database updated June
2015).
80
Jake Gipson, Patentable Subject Matter: A Myriad of Problems, 65 ALA. L.
REV. 815 (2014).
81
Id.
82
Id.
83
“Since biotechnological processes are inherently low-energy and renewable,
they are being utilized to provide solutions for some of the world's problems. In
agriculture, the bacterium Pseudomonas syringae has been modified to impart frost
76
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the agriculture and pharmaceutical fields.84 For example, patents
have been procured in order to diagnose patients with genetic
mutations using deoxyribonucleic acid (DNA).85 All genetic material
is comprised of the biochemical substance known as DNA,86 and this
includes the genetic material found in all living organisms.87 DNA is
a double helix shaped molecule, made of two linear chains made
from adenine, guanine, cytosine, and thymine nucleotide bases.88
An ordered sequence of these nucleotide bases within the DNA,
located in a particular position on a particular chromosome may
constitute a gene.89 These genes encode a specific functional product
such as a protein.90 “One of the challenges with respect to DNA is
that it is an upstream tool for basic research (e.g. PCR91), a medically

protection to plants by deleting a gene for a protein that nucleates ice crystal
formation.” Dastgheib-Vinarov, supra note 12 at 146. Also, “Industrial
applications of biotechnology include engineering microorganisms to be used to
clean up oil20 and chemical spills. Bioengineered biodegradable plastics offer
solutions to the world's growing waste disposal problem.” Id. at 147. “Medical
benefits of biotechnology include the development of new drugs and enhanced
production of old drugs that combat cancer, A.I.D.S., dwarfism, diabetes, hepatitis,
and even aging.” Ned Hettinger, Patenting Life: Biotechnology, Intellectual
Property, and Environmental Ethics, 22 B.C. ENVTL. AFF. L. REV. 267, 272 (1995).
84
Biotechnology, WORLD INTELL. PROP. ORG.,
http://www.wipo.int/patents/en/topics/biotechnology.html.
85
Christopher Bergin, Take Off Your Genes and Let the Doctor Have A Look:
Why the Mayo and Myriad Decisions Have Invalidated Method Claims for Genetic
Diagnostic Testing, 63 AM. U. L. REV. 173, 177 (2013) (“[D]iagnostic patents have
three basic steps: (1) obtaining a DNA sample from a patient, thereby establishing a
providing, collecting, or obtaining step, (2) sequencing that DNA sample, and (3)
comparing the patient's DNA sequence to other known wild-type and mutant
strands to determine if the patient has a mutation.”). Id.
86
WORLD HEALTH ORG., supra note 1 at 2.
87
www.genome.gov
88
Id.
89
Id.
90
Id.
91
“PCR (short for Polymerase Chain Reaction) is a relatively simple and
inexpensive tool that you can use to focus in on a segment of DNA and copy it
billions of times over. PCR is used every day to diagnose diseases, identify bacteria
and viruses, match criminals to crime scenes, and in many other ways.” PCR,
LEARN GENETICS, (2015), http://learn.genetics.utah.edu/content/labs/pcr/.
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valuable product (e.g. gene therapy92), as well as vital information
about the molecular basis for disease.”93 The basis for studies to
develop therapeutics, and for immediate use in laboratories, is
therefore sometimes dependent on some individual patents.94 One of
the DNA’s most significant contributions has been the
pharmaceutical use of DNA to develop large-molecule proteins, such
as insulin, growth hormone, growth factors, and blood-clotting
factors, to treat serious diseases.95 Additionally, DNA has embedded
within it, information about the future of an individual’s health.96
“DNA genetic testing involves the analysis of DNA in order to
determine the presence a gene associated with a particular disease.”97
These tests come in four general varieties: carrier testing98, prenatal
testing99, diagnostic testing100, and predictive testing101.102 It is clear,
that the isolation of genes from DNA is a very valuable tool to the

92

“Gene therapy could be a way to fix a genetic problem at its source. By
adding a corrected copy of a defective gene, gene therapy promises to help diseased
tissues and organs work properly. This approach is different from traditional drugbased approaches, which may treat symptoms but not the underlying genetic
problems.” What is Gene Therapy?, LEARN.GENETICS (2015),
http://learn.genetics.utah.edu/content/genetherapy/gtintro/.
93
WORLD HEALTH ORG., supra note 1 at 48.
94
Id.
95
Id.
96
Id.
97
Id.
98
“Carrier testing determines if the person tested, who does not himself have
the disease, carries a gene for the disease. If two carriers have a child together,
there is a high probability that their offspring will have the disease.” Id.
99
“Prenatal testing determines whether a fetus is affected with a genetic
abnormality causing a particular condition. Embryos may also be tested during in
vitro fertilization before being surgically implanted into the womb; this is called
pre-implantation diagnosis. For technical reasons, the latter method is not widely
practiced.” WORLD HEALTH ORG., supra note 1 at 48.
100
“Diagnostic testing determines whether the tested individual in fact has a
particular genetic condition or a genetic predisposition for acquiring the condition
later in life.” Id.
101
“Predictive testing determines the presence in asymptomatic individuals of
an abnormal gene that will lead to a disease in the future, or of a genetic
predisposition for acquiring the condition later in life, in interaction with
environmental factors.” Id.
102
Id. at 4.
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medical community.
The USPTO states that, “a patent on a gene covers the isolated
and purified gene but does not cover the gene as it occurs in
nature.”103 According to this view, what distinguishes a DNA
sequence that exists naturally in a cell or organism from a patentable
DNA sequence is that the former owes nothing of its existence to a
human inventor, while the latter would not exist without some form
however minimal of human intervention.104
Once an isolated gene has been deemed an “invention” for patent
purposes, the gene sequence must still have some distinguishable
utility, and some sort of invented step must be demonstrated to meet
the nonobvious standard.105 “In general, DNA patents claim at least
one of the following four applications of DNA sequences: diagnostic
testing, research tools or methods, gene therapy or methods, or the
production of therapeutic proteins to be used as medicines.”106
In some areas, there is evidence that an increase in the amount of
patents has not been accompanied by a proliferation of medical
applications.107 Undoubtedly, the lag between patents and medical
applications is in some ways attributable to the complex nature of the
science, as well as to technical issues.108 “[I]t is unclear how much is
related, if only indirectly, to a failure of incentive mechanisms,
including patents, to generate new and useful products and
services.”109
B. Ethical Objections
Many ethical concerns have been expressed regarding the
modification of human biological material.110 “It has been claimed
that it is unacceptable for people to have ‘proprietary rights in living
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beings and tissues,’111 and that market logic now holds sway over the
use of living organisms (or their component parts).”112 The United
Nations Educational, Scientific and Cultural Organization’s
Declaration on the Human Genome and Human Rights makes the
claim that the human genome is the “common heritage of
humankind.”113 This implies that DNA goes beyond existence as
regular biological molecule, and that it also includes some sort of
special character.114 “Human DNA is common to all human beings
(DNA itself is common to all living things), past and present.
Therefore, DNA is foundational not only biologically, but also
historically and even morally; in its’ significance.”115
Genetic material, in essence is knowledge and information, and
typically knowledge and information is seen to be beneficial to the
public.116 “Genomics knowledge is nonrivalrous in consumption (not
depleted by use), and is usually made public by genomics databases
on the Internet and journal publication, as was the case with the
malaria and mosquito genome.”117 “It is a global public good in the
sense of the knowledge not being bound by national border, in
discovery, transmission, or use. Further, the global public-good
nature of genomics is reflected in the way in which the Human
Genome Project was funded and undertaken.”118
The Agreement on Trade-Related Aspects of Intellectual Property
Rights (TRIPS Agreement) leaves space for countries to do precisely
this. According to Article 27 of TRIPS:
Members may exclude from patentability inventions, the
prevention within their territory of the commercial exploitation of
which is necessary to protect ordre public or morality, including to
protect human, animal or plant life or health or to avoid serious
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prejudice to the environment, provided that such exclusion is not
made merely because the exploitation is prohibited by their law.119
C. Legal Issues
It is often argued that DNA, in certain cases, is not suitable as
patentable subject matter when the legal requirements for patents are
applied strictly.120 One concern is that because genetic material is
essentially information; therefore, DNA’s value is primarily in the
information within the material and not in the material qualities of
the DNA itself.121 Given this viewpoint, this represents a departure
from patent doctrine, “. . . which is based on an agreement to disclose
information in exchange for giving the inventors’ rights over the
material invention.”122 “If DNA itself has value not only as material,
but also, if not primarily, as information, this moves away from the
usual range of patentable material and presents a new challenge for
those who need access to the information.”123
In the first instance, there has been concern about the requirement
of an “inventive step”, given that the sequencing of DNA, once a
laborious manual task, has become a highly automated and routine
part of laboratory practice. In the United States, the Court of Appeals
for the Federal Circuit’s interpretation of the “non-obviousness”
standard has explicitly denied that the difficulty or complexity of
invention matters at all in the determination of patentability.
Additionally, there has been questioning of the granting of patents for
sequences of questionable or limited utility. Some of this controversy
has abated with the USPTO’s 2001 guidelines on expressed sequence
tags (ESTs, short pieces of DNA that help to identify when particular
genes are being expressed in cells), which tighten the specifications
regarding what constitutes “utility”.124
The amount of creative energy and the technical difficulty
119
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required to acquire this genetic knowledge may be the factor
determining whether or not something may be patented.125 Some
consider that the isolation and sequencing of genetic material takes
little creative energy and difficulty, and requires only a basic
competence.126 On the other hand, it may take great effort in order to
identify the link between a disease and a particular gene depending
on the “complexity of the interactions involved.”127
D. Biotechnology and the “Big Freeze”
“Entities from industrialized countries currently hold 97% of all
patents worldwide. The rise in patents in biotechnology has been
particularly dramatic, climbing by 15% per annum from 1990 to
2000 at the UPTO.”128 The growth of patents in the biotechnology
field has been heavily influenced by the public sector.129 “For
example, public institutions in Europe and the United States own
30% of all the patents for DNA sequences filed between 1996 and
1999.”130
And “start-up companies have a higher share of
biotechnology patents than do large, established pharmaceutical
companies.”131
The most basic argument in favor of granting these biotechnology
patents is, as applicable to all types of patents, simply that people are
naturally entitled to the fruits of their labor.132 Patents are arguably
necessary to make innovation profitable because patents grant the
opportunity for a patent holder to exclusively profit from her work.133
Locating, isolating, and describing biomolecular matter requires
considerable ingenuity, and, as a result, the biotech industry argues
that, without strong patent protection, firms could not justify the risk,
time, energy, and money necessary to create new pharmaceutical and
125
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agricultural products.134 Additionally, companies argue that, if they
are to continue producing new drugs and therapies for the treatment
of disease, the public may be best served by allowing life forms and
their structural components to be patented as inventions.135 This
protection may be particularly critical for start-up biotechnology
companies that need to attract capital; for intellectual property is
often the sole asset of the company.136 A shift in the way in which
organizations do research has been sparked by this rapid increase in
biotechnology patents.137
According to a recent report by the Organisation for Economic
Cooperation and Development: Not only have new types of
inventions—software, genetic, and business methods—been deemed
patentable by some patent offices, but the ability of patent holders to
protect and enforce their rights has also increased, leading many to
call the past two decades a pro-patent policy era.138
While the current system promotes innovation by rewarding
innovators early in the developmental stages, this early reward “could
hinder those conducting important research or providing needed
services downstream, and can inhibit cumulative innovation.”139 This
may be the result when licenses for patents granted prematurely
restrict the amount of research that may be conducted.140
Those opposed to living material patents specifically oppose
those patents granted on single-function genes.141 Often, these
single-function genes must be combined with other genes in order for
research to progress, and this often creates a “freezing” effect on
biotechnology research because permission must be granted before
any previously patented genes may be used to further the research.142
Thus, granting patents on genes when they are pre-market or while
134
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they are still upstream in the research process may be stifling lifesaving innovations further downstream in the course of research and
development.143 Furthermore, the increased protection on genes may
be raising the overall cost of research and development because a
company that wishes to use the results of other research is bound to
incur large costs in acquiring licenses to use other patents.144 As a
result, the field of biotechnology faces the “tragedy of the
anticommons,” where a resource is prone to underuse when multiple
owners each have a right to exclude others from a scarce resource
and no one has an effective privilege of use.145 “This debate reflects a
fundamental controversy about whether DNA ought to be treated
specially, or the same as any other molecule.”146
IV. THE HISTORY BEHIND GENE PATENTS
In 1953, James Watson, Francis Crick, and Maurice Wilkins first
discovered DNA and pulled at the first thread to unravel the mystery
blanketing genetics and heredity.147 This scientific leap was made
possible by several scientific breakthroughs, including:
[P]rogress made by X-ray crystallographers in studying organic
macromolecules; the growing evidence supplied by geneticists that it
was DNA, not protein, in chromosomes that was responsible for
heredity; Erwin Chargaff’s experimental finding that there are equal
numbers of A and T bases and of G and C bases in DNA; and Linus
Pauling’s discovery that the molecules of some proteins have helical
shapes—arrived at through the use of atomic models and a keen
knowledge of the possible disposition of various atoms.148
143
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Jointly, Watson, Crick, and Wilkins received the 1962 Nobel
Prize in physiology or medicine for their contribution to science.149
In 1980, the Supreme Court held that a genetically engineered
strain of bacteria “with markedly different characteristics from any
found in nature” was patentable.150 Patents for plants, animals, and
micro-organisms such as cell lines and DNA became increasingly
common, for Congress began encouraging universities and other
institutions to patent discoveries arising from federally supported
research and development.151
A decade later, the Supreme Court of California provided the first
clear rule regarding an individual’s right to his or her own genetic
material in Moore v. Regents of University of California.152 In
Moore, a leukemia patient underwent treatment at the UCLA Medical
Center.153 It was later discovered by the patient that his white blood
cells had been used to create a cell line that would be used for the
medical center’s financial benefit.154 When Regents of the university
applied for a patent on the cell line,155 the patient filed suit against his
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physician and the Regents of the University of California.156 To the
patient’s dismay, the court found that the patient had no property
rights to his discarded cells and was not entitled to any profits
resulting from the cell line.157
A year later, biotechnology patentability broadened when the
Federal Circuit upheld the patentability of human DNA sequences
that are “purified and isolated” from the original object in nature.158
Then in 1995, the United States Court of Appeals for the Federal
Circuit ruled on a controversial issue in In re Deuel.159 Deuel used
uterine and placental cells to isolate the DNA and growth factor
sequences of a protein called heparin-binding growth factor
(“HBGF”). Deuel’s claims were rejected for “obviousness” after the
patent examiner and Board determined that the HGBF was the same
as another protein, heparin-binding brain mitogen (“HBBM”).160
Deuel appealed the rejection.161 The Court ultimately ruled in favor
of Deuel, finding that, regardless of whether Deuel used the general
method for isolating DNA or not, the location of the protein was not
aided by the discovery of the prior HBBM.162 Thus, the DNA
molecules encoding the protein were nonobvious under section 103
of the Patent Act.163
In 1996, however, the patentability trend took a turn when the
“Strategy Meetings on Human Genome Sequencing” resulted in an
agreement that all raw sequence data from the human genome
sequencing efforts should be “freely available [to] the public
domain.”164 The organization that coordinated this effort was the
Human Genome Organisation (HUGO).165 “Partners in this initiative
[have] articulated their commitment to making their results rapidly
156
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available, and to placing them in the public domain.”166 “British
Prime Minister Tony Blair and then-President of the United States
Bill Clinton issued a joint statement, affirming that: ‘To realize the
full promise of this research, raw fundamental data on the human
genome . . . should be made freely available to scientists
everywhere.’”167 The patenting of DNA was not ruled out.168 It was
later added that “[i]ntellectual property protection for gene-based
inventions will also play an important role in stimulating the
development of important new health care products.”169 In the same
vein, in 2001 the United States Patent Office revised its guidelines to
emphasize that patents must show specific, substantial, and credible
utility – a “real world context for using the invention.”170 The main
driver of advances from the human genome was a project led by
scientists all over the world called The Human Genome Project.171
This project was “an approach to the large-scale sequencing and
analysis of DNA that continues to have an enormous impact on how
biomedical research is done in laboratories around the world.”172
Many similar projects seeking to sequence the genomes of many
organisms have arisen from the Human Genome Project – “from
useful laboratory animals to deadly disease-causing agents.”173
Although “laws of nature, natural phenomena, and abstract ideas”
are not patentable subject matter under § 101 of the Patent Act,174 “an
166
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application of a law of nature . . . to a known structure or process
may [deserve] patent protection.”175 In 2012, the Supreme Court
affirmed in the biotechnology world that “(1) a newly discovered law
of nature is itself unpatentable and (2) the application of that newly
discovered law is also normally unpatentable if the application
merely relies upon elements already known in the art.”176 In Mayo
Collaborative Services v. Prometheus Labs., Inc., the Court
considered two method patents held by Promethium Labs for
methods used to determine the appropriate amount of medication to
administer to a patient with Crohn’s Disease.177 The Court
conducted its inquiry by looking at each step described in the
method178 “to consider whether any of the steps added anything to
the law of nature that was not
‘well-understood, routine, conventional activity.’”179
The
“administering” step,180 the “wherein” step,181 and the final
“determining” step182 were all considered individually. The Court
then evaluated the method as a whole to see if the method contributed
anything new to the laws of nature.183
Most recently, the Supreme Court considered the validity of gene
patents in Association for Molecular Pathology v. Myriad Genetics,
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Inc.184 Litigation in Myriad transpired from a global search to find
the genetic basis for breast and ovarian cancer.185 Myriad Genetics
was founded in 1994 as a startup company out of University of Utah,
by scientists involved in the hunt for the BRCA genes.186 Later that
year, Myriad filed the first patent for BRCA 1,187 and within the next
year, Myriad had isolated and patented a second gene associated with
breast cancer, the BRCA2 gene.188 Suit was filed against Myriad,
seeking declaration that Myriad’s BRCA1 and BRCA2 patents were
not patentable subject matter under § 101 of Title 35 of the United
States Code.189 The primary plaintiff in the action was the
Association for Molecular Pathology (AMP), which actively lobbied
against the licensing and existence of gene patents.190 AMP argued
that the genes were unpatentable because they were products of
nature that had merely been isolated,191 and that no real world
transformations occurred to the genes in the process of isolation.192
The Court ultimately came to the holding that the process of isolating
184
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DNA involves naturally occurring segments of DNA, thus precluding
patentability.193 However, it also held that cDNA194 is not naturally
occurring and remains patent eligible.195
V. ANALYSIS: ARE WE LOOKING IN THE RIGHT PLACE?
A.The Nonobvious Requirement
In response to many of the issues that have arisen from gene
patenting, and in proposing a solution, much attention has been given
to the nonobvious requirement.196 Whether an invention is obvious is
determined by asking whether a person of ordinary skill in the art,
who knew all of the invention's prior art, would have had a
reasonable expectation that the invention would work.197 In 1966 the
Supreme Court in Graham v. John Deer Co. looked at multiple
factors to determine whether an invention was obvious.198 The
analysis in Graham provided a step-by-step method of evaluating the
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nonobvious requirement.199 First, differences in the prior art and the
claims at issue are determined based on the scope and content of the
prior art.200 Then, the level of ordinary skill is resolved to determine
whether the “subject matter as a whole would have been obvious at
the time the invention was made to a person having ordinary skill in
the art.”201 The Court also noted that, to give light to the
circumstances surrounding the origin of the subject matter, it might
need to use “secondary considerations.”202
These Graham factors remained in use from 1966 until 2007
when the Supreme Court once again considered the nonobvious
requirement..203 In that time, lower courts developed a “teaching,
suggestion, or motivation” or “TSM” test that was to be applied aside
from the Graham factors.204 In application, courts contemplated
whether there was a suggestion or motivation to combine known
elements in prior art references.205 The Supreme Court assessed the
use of this TSM test in 2007 in a case called KSR Int’l Co v. Teleflex,
Inc.,206 holding that the TSM test was too rigid in application.207 The
Court held that “the fact that a combination was obvious to try might
show that it was obvious under § 103,”208 which led to the obvious to
try standard that provides the background to obviousness as it relates
to gene patenting.209
Much of the current patent law was developed between the
Graham factors and the obvious to try standard.210 Regarding the
patenting of a naturally occurring gene, the Federal Circuit concluded
in 1970 that “an unknown compound or composition of materials
199
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merely discovered from nature is not patentable.”211 In 1980, the
Supreme Court in Diamond v. Chakrabarty allowed the patenting of
a living organism.212 The living organism had been genetically
altered, and the Court noted that since “Congress intended statutory
subject matter to ‘include anything under the sun that is made by
man,’”213 a genetically modified organism was patentable as a
“product of human ingenuity.”214
In 1995, “[t]he Federal Circuit held in [In re Deuel] that a “DNA
[in ][w]hich the [p]rotein [p]roduct [i]s [h]omologous to a [k]nown
[p]rotein [i]s [n]ot [o]bvious.”215 As discussed, Deuel had tried to
patent a sequence that encoded a protein that was not known to
anyone at the time.216 However, there was a similar protein with a
known function disclosed in previous experiments.217 Because
Deuel’s sequence shared similarity to the sequence of the previously
disclosed protein, the USPTO rejected the patent application for
being obvious.218 “[T]he court focused on a criterion familiar to old
time chemists whose main way to design new compounds was
molecular modification--structural similarity.”219
“[T]he court
focused on the ‘consequences of genetic code's redundancy on
DNA's obviousness, asserting that it precludes contemplation and
conception of the exact structure of cDNA molecules.’”220 The
Federal Circuit reversed the USPTO rejection by reasoning that
“because of the redundancy in the genetic code, countless possible
DNA sequences could code for the protein.”221 As a result, “a person
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of ordinary skill in the art could not have determined the DNA
sequence without actually doing the experiment performed in
Deuel.”222 As it stands today, for naturally occurring DNA
molecules, if their functions described in the patent applications
agree “with the prediction based on its sequence homology to a
protein with a known function, it is not patentable on the ground of
nonobviousness.”223 But, if there is a discrepancy between the
predicted function of a naturally occurring DNA molecule, as
described in the patent application, and the function, as predicted
based on its homology to a protein with a known function, it may
meet the nonobvious standard.224
It is no surprise that there has been much concern involving the
nonobvious standard. Granting exclusive rights to an obvious
invention contributes significantly to the problems that coincide with
gene patenting. Concern has been expressed that if the bar is set too
low for achieving nonobviousness, then public fear regarding genetic
privacy will result in fewer donations of genetic information that will
hinder research and testing.225 There are additional arguments in
favor of a heightened standard for nonobvious that hinge on the
availability of genetic information to researchers and scientists.226
New strategies have been developed since the 1980’s that make it
easier to obtain cDNA and genes in the laboratory.227 “[C]ompanies
are using state of the art technologies from various fields to reduce
the guesswork and increase the accuracy and certainty in performing
previously lengthy recombinant DNA procedures.”228 Also, private
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and public databases containing genomic research have become more
readily available, making the “invention” of cDNA seemingly more
obvious.229 Freely accessible databases have been made available to
the public by the government.230 Some of these governmental
databases “include the National Genbank, developed by the National
Institutes of Health (NIH), and dbEST, the database for expressed
sequence tags.”231 In the private sector, there are companies making
money by charging for access to their sequenced gene databases.232
To name a few: “Incyte, ‘Sequana Therapeutics in San Diego,
Millenium Pharmaceuticals in Cambridge, Massachusetts, and
Myriad Genetics in Salt Lake City, Utah.’”233
Clearly, the degree of obviousness can interfere with the
underlying principles which give rise to the social value of
patenting.234 The patenting of small molecules for drugs has been
illustrative of this point.235 At times, the degree of ingenuity behind
an invention is overshadowed in valuations in favor of the time and
money invested in the development of the invention.236 “Patents, in
this case, are principally to induce investment rather than to
encourage innovation.”237
Once the general population seemingly accepted the notion that
genetic material may qualify as an invention opposed to a mere
discovery, most of the attention has been aimed at adjusting the
nonobvious standard to remedy the problems arising from gene
patents. Though many great arguments have been presented, and
many solutions have been recommended, nonobviousness is but one
patent requirement. Directing our attention elsewhere, and perhaps
assessing all facets of the system, may enable us to shed light on
additional weaknesses within the current system – the correction of
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which may also help to alleviate the anxiety caused by genetic
patenting.
B.The Uselessness of the Utility Requirement
As discussed, the main focus for those who want to better the
current patent system has been on the nonobvious requirement. By
no means should the nonobvious requirement be taken lightly. It is a
very important aspect of the process and illuminates the policy
behind granting patents at all. Strong arguments have been presented
to adjust the nonobvious requirement, and progress has been made as
a result of those arguments. Nonobviousness, however, is but one
symptom to be treated in a greater illness. For purposes of this
Comment, let us pretend that nonobviousness is a hurdle that has
already been cleared, and now direct our attention to the usefulness
of these genetic patents.
Notwithstanding the other patent
requirements, it appears that genetics patents that have been granted
prior to the patented idea are ambiguous when it comes to their use.
The usefulness requirement is being met on credit. Patentees are
granted patents on ideas that show promise, but not utility, and this
current system is contributing greatly to icing the momentum of
innovation.
Two cases that illustrate this point are Myriad and Chakrabarty.
Both cases involve patents granted for something that has been
tweaked in the laboratory to make it different enough from the
natural counterpart to qualify it for patent protection. Both cases
were analyzed through the lens of the nonobvious requirement – that
is, it was the Court’s resolve to settle whether it was obvious to use
naturally occurring materials in inventing something else. The end
result in both was the same. The reasoning in Myriad is that, though
DNA is found in nature, the cDNA for which a patent was sought is
not.
Thus, the cDNA met the nonobviousness requirement.
Similarly, in Chakrabarty, though a bacterium was found in nature,
the genetically modified bacterium for which the patent was sought
was not found in nature. Therefore, the genetically modified
bacterium was not obvious and was eligible for patent protection.
In Chakrabarty, the genetically modified bacterium was
developed to treat oil spills, for the bacterium had been put to use and
was capable of breaking down crude oil.
Therein lies the key
difference between the patent sought in Chakrabarty and the patent
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sought in Myriad – the known usefulness of the invention. Take a
moment to compare the language of the Chakrabarty patent to one of
the patents at issue in Myriad. The Chakrabarty patent states that
“[t]he versatility of these novel [bacterium] has been demonstrated
by the substantial extent to which degradation of such complex
hydrocarbons as crude oil and Bunker C oil has been achieved
thereby.”238 Myriad’s claim, on the other hand was that
[t]he present invention relates generally to the field of human
genetics. Specifically, the present invention relates to methods and
materials used to isolate and detect a human breast and ovarian
cancer predisposing gene (BRCA1), some mutant alleles of which
cause susceptibility to cancer, in particular breast and ovarian cancer.
More specifically, the present invention relates to germ line
mutations in the BRCA1 gene and their use in the diagnosis of
predisposition to breast and ovarian cancer.239
The difference is clear that, from the language of the patents,
Myriad had not proven the usefulness of the BRCA1 gene. The
patent was applied for based on a known affiliation with breast
cancer, but only a presumption that the BRCA1 would be useful in its
treatment. It may be true that the presumption was strong based upon
BRCA1’s gene sequence homology to other genes with a known
function, but why not hold the patent applicant responsible for
showing actual use in practice? Would that not expand the window
in which additional research can be conducted by third parties before
they are required to obtain a license to use the gene?
The current usefulness standard in general is that a new product is
“not useful only when it is incapable of achieving any beneficial
function or use in any application and under any consequences.”240
In regards to new chemicals, patents are only to be granted upon the
disclosure of some specific utility by the new chemical.241 In In re
Kirk, the court found that the application failed to describe a useful
invention.242 The patent application claimed that the new compounds
could be converted into something useful, but did not make a claim
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of usefulness regarding the new compounds themselves.243 It was
held that the new compound was not useful in the patent sense
because the only use of the new compound was to make other
compounds that showed promise in being useful.244
The bar is set slightly lower when applying to patent a
pharmaceutical drug. Inventors are only required to show potential
therapeutic use in application.245 Various types of research that might
indicate potential therapeutic benefits are disclosed in the patent
application.246
Because testing does not necessarily involve
experiments that accurately mimic the way in which a
pharmaceutical will be used once it hits the market, researchers are
often forced to jump to conclusions regarding the effect the
pharmaceutical will have, and thus the usefulness requirement is
significantly easier to achieve for chemicals if the inventor proposes
a pharmaceutical use.
The interests of inventors are kept in mind with both of these
standards. Significant effort is expended in developing a new
chemical or pharmaceutical drug. It is only right that protection is
granted to ensure that this effort is rewarded. Because, testing on
humans may pose a risk to the test subject, raising many ethical
concerns as a result, it is much harder to obtain sufficient data when
testing pharmaceutical drugs than it is to obtain data on new
chemicals that can be tested without a live test subject and do not
raise the same ethical concerns. It makes sense to loosen the
usefulness standard in this case in order to encourage the
development of marketable pharmaceuticals. Where do genetic
patents fall in relation? A gene sequence has a chemical structure of
its own and could be treated as a new chemical, and many genes are
eventually put to pharmaceutical use.
Arguably, standard methods of obtaining gene sequences in the
lab and accessible databases containing genetic information make it
even easier to isolate a gene from DNA than to develop a new
chemical using nothing as a template. In other words, researchers do
not have as much effort vested when they apply for a genetic patent.
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Regardless, many genes being patented receive more lenient
treatment than other pharmaceuticals. As seen in Myriad, usefulness
is achieved based on homology to the function to known genes with
similar sequencing. This means that usefulness may be achieved
prior to the development of a pharmaceutical being derived from the
gene, and well before the standard applied to pharmaceutical drugs
that requires that testing then be conducted on the derived
pharmaceutical that may propose a use. If less energy is being
expended on isolating genes, and if pharmaceuticals that are not
derived from DNA are held to a heightened showing of usefulness,
then the standard for genetic patents should be that, at a minimum,
research using the derived pharmaceutical must be presented in order
to show usefulness. Or, better yet, using the logic of In re Kirk, gene
patents should not qualify as a useful invention when their usefulness
comes from creating something else that has a clear use. Patents
would then be reserved only for the products derived from the
isolated genetic material, and the genetic material itself should be
rendered ineligible.
Admittedly, heightening the usefulness standard would have no
impact on ethical concerns. It is still up for debate whether DNA, the
key to unlocking nature, is something that humans should tamper
with at all. Also, whether or not genes are discoveries or inventions,
an issue that may be addressed again in the near future, remains
unaffected by a heightened usefulness requirement. It is likely,
however, that both of these issues are in our rearview and focusing
on them would be fruitless in trying to change the future of genetic
patenting. So, what impact could a heightened usefulness standard
actually have?
A heightened usefulness would have no impact on the underlying
principles of patent law. Effectively, all a heightened standard would
do is adjust the timing for when reward is received for the fruits of a
researcher’s labor. Researchers still get their reward, but only upon
the showing of an invention that has proven itself useful. That is, a
researcher would only be rewarded once it is shown that he has
upheld his end of the deal. This does not eliminate the incentive for
researchers to invent, and the additional burden in showing actual
usefulness is not significant enough to deter companies and
institutions from conducting research. A heightened usefulness
standard, in reality, only brings the usefulness requirement into
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existence. For, as of now, usefulness is not really required at all for
genetic patenting.
Undoubtedly, complaints will arise from corporations because
some profits will be lost if they are unable to obtain patents prior to
developing a pharmaceutical from an isolated gene. This is true.
Some profits will be lost. However, those lost profits are the profits
that come from licensing genetic patents to outside researchers who
may be able to put the isolated genes to use – the lost profits would
be those profits that are fueled by the “Big Freeze,” by hindering
research, and by stunting the growth of innovation. If the goal of
patents is to protect innovators, and if an innovation is something
new, not obvious, and useful, then corporations will not lose any
money earned from patents that comply with this goal. If
corporations can put out a product that is of use to society, then they
shall receive protection and shall earn the right to profit from the
fruits of their labor.
Genetic patents are being granted on a promise that a use will be
found. No more promises. A heightened usefulness standard creates
an otherwise unopened window of advancement. For, in the time it
takes for an individual who isolated a gene to demonstrate the
usefulness of it, many other uses could simultaneously be found by
many other scientists. Research could flourish as licenses would no
longer be needed in order to use a genetic sequence, and the
expenditures that would have gone towards a license could now be
fed back into research and additional innovation. The incentive to
invent would remain, but the “Big Freeze” would be no more.
VI. CONCLUSION
Stemming from the United States Constitution, patents are an
integral part of American culture, capitalism, and business. Patents
protect the innovative, guaranteeing that they will be rewarded for
the inventions they create. Patents are supposed to inspire profit and
growth, and ensure that the public will see the benefit. On occasion,
the unfortunate truth is that plenty of profits are made, but society
does not see the benefit. Instead, patents necessary to further
research hinder and delay research – defying the goals of the patent
system. Genetic research has led to significant societal contributions
in agriculture, as well as in the medical field with the development of
new pharmaceuticals. More recent research shows great promise.
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However, sometimes research requires collaborative efforts and
multiple licenses must be obtained in order to progress. Maybe that
is just the price that must be paid to play the game – or maybe the
patents that are hindering research should be reconsidered.
Patenting genetic material has raised several issues. Some have
contemplated the ethics of tampering with our own genetic material.
Some have argued that DNA is naturally occurring, and should not
qualify for patent protection at all. As it stands, patents to protect
genetic material are constantly being granted, and we are still in the
midst of the “Big Freeze.” Because of readily available genetic
information and streamlined laboratory techniques, serious
reconsideration of the nonobvious standard has occurred. This
reconsideration may be necessary, and the nonobvious standard may
be a real issue that should be dealt with – but it is not the only issue.
The standards for meeting the usefulness requirement are nearly
nonexistent when dealing with genetic patents. The requirement is
met on credit. A patent applicant need not show that the gene
sequence is useful, but merely promise that it might be useful with
further research. If patent applicants are held to the burden of
actually producing enough data to show a use, the window of
opportunity for other researchers to take full advantage of the soonto-be-patented gene. Likely, the only use the gene has is that it will
be used to produce something else, such as a protein that may be used
to develop pharmaceuticals. If this is the case, then a patent should
be granted on the pharmaceutical, but the gene sequence should
remain unpatentable until a direct use is shown. Researchers who
find the locations of previously undiscovered gene sequences will
still be incentivized, but the incentive will come from inventing
something from the genetic material they have replicated. Businesses
will oppose this idea. Profits in licensing will be lost, but the
integrity of the patent system will remain intact. Sometimes it is
necessary to take a step back and ask, “What’s the use?”

